Compare UHT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | DSGN |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.2M | 579.9M |
| IPO Year | 1995 | 2021 |
| Metric | UHT | DSGN |
|---|---|---|
| Price | $40.05 | $10.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 52.7K | ★ 257.0K |
| Earning Date | 04-27-2026 | 03-09-2026 |
| Dividend Yield | ★ 7.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $31.34 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $2.62 |
| 52 Week High | $44.70 | $11.23 |
| Indicator | UHT | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 53.32 |
| Support Level | $38.72 | $9.64 |
| Resistance Level | $41.64 | $11.18 |
| Average True Range (ATR) | 1.08 | 0.59 |
| MACD | -0.42 | 0.02 |
| Stochastic Oscillator | 11.22 | 55.19 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.